Clinical Therapeutics 2011-01-01

Iloperidone for the Management of Adults with Schizophrenia

Brian L. Crabtree, John Montgomery, Brian L. Crabtree, John Montgomery

文献索引：Clin. Ther. 33(3) , 330-45, (2011)

全文：HTML全文

摘要

Background Iloperidone is a second-generation antipsychotic drug approved in May 2009 by the US Food and Drug Administration (FDA) for the acute treatment of schizophrenia in adults. It is a piperidinyl-benzisoxazole derivative with mixed serotonin (5HT2A) and D2 dopamine antagonist properties.